![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
Cryptocurrency News Articles
Hashdex Applies to SEC to Expand Its Cryptocurrency Index ETF
Mar 19, 2025 at 11:00 pm
Hashdex, a Brazil-based asset manager specializing in digital assets, has applied to the U.S. Securities and Exchange Commission (SEC) to expand its cryptocurrency index ETF.
Hashdex, a Brazil-based asset manager specializing in digital assets, has applied to the U.S. Securities and Exchange Commission (SEC) to expand its cryptocurrency index ETF.
The move comes as part of Hashdex’s strategy to enlarge its portfolio assets with two additional altcoins: XRP and Cardano (ADA).
This new corporate direction is driven by the expanding market need for numerous crypto investment choices.
ETFs accept new cryptocurrencies after they fulfill specific qualifications. The cryptocurrencies need to be accessible on Bitstamp and Coinbase as well as Gemini for trading on major exchanges.
The selected cryptocurrencies need independent pricing, which means their market value should not derive from other assets. The set requirements enhance both liquidity and transparency during investments.
The Brazilian Securities and Exchange Commission (CVM) provided approval in February 2024 to Hashdex for creating the world’s initial XRP spot exchange-traded fund (ETF). The approval empowered Hashdex to expand its reach as a global leader in crypto investment markets.
Hashdex Joins ETF Rush Amid Changing Crypto Regulations
Security along with reputation factors serve as additional criteria for Hashdex when choosing investment assets. Economic fundamentals and innovative use cases act as essential criteria for crypto tokens to gain inclusion because weak fundamentals and lack of unique use cases result in exclusion.
The firm has explicitly mentioned that meme cryptocurrencies will face exclusion from their ETF offerings.
The funds managed by Hashdex’s Nasdaq Crypto Index Fund (NCIQ) currently hold assets worth $66 million but have objectives to grow. The fund evaluation team intends to add XRP, Solana, Cardano, Chainlink, Uniswap, Litecoin, and Avalanche to its portfolio.
The increased digital assets included in the expansion would likely draw more institutional investors who want diversified crypto investments.
The revised filing presents itself as regulatory attitudes toward cryptocurrency change. The crypto industry gained optimism when U.S. President Donald Trump announced his decision to relax existing crypto regulations. Hashdex joins many other asset management companies that expedite their crypto ETF application submissions to earn regulatory approval.
The expanded Hashdex ETF would provide investors with new opportunities and enhance crypto market credibility if it receives approval. Investors and industry leaders are watching closely to see how regulators respond to these developments.
Disclaimer:info@kdj.com
The information provided is not trading advice. kdj.com does not assume any responsibility for any investments made based on the information provided in this article. Cryptocurrencies are highly volatile and it is highly recommended that you invest with caution after thorough research!
If you believe that the content used on this website infringes your copyright, please contact us immediately (info@kdj.com) and we will delete it promptly.
-
-
-
- Blurring the Lines Between Decentralized Finance and Traditional Finance, Ripple's XRP Ledger (XRPL) Is at the Center of a New Attempt to Integrate Blockchain into the Heart of Institutional Trading
- Apr 21, 2025 at 11:50 pm
- The lines between decentralized finance and traditional finance continue to blur now, Ripple's XRP Ledger (XRPL) is at the center of a new attempt to integrate blockchain into the heart of institutional trading.
-
-
-
- Novo Nordisk (NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019. Yet the stock has since plummeted 60% from its peak value.
- Apr 21, 2025 at 11:45 pm
- Despite strong growth and earnings momentum, the Danish biotech giant faces scrutiny over its positioning in the rapidly changing market for GLP-1 receptor agonists, as competition intensifies.
-
-
-